Tezspire reduced swelling in the esophagus.
Swallowing problems improved for patients.
The study used a placebo control group.
The drug is already approved for severe asthma worldwide.
The result helps the company after earlier setbacks in heart and cancer trials.
Participants also reported less difficulty swallowing compared with those who received a placebo.
The positive result comes after the company faced several recent trial failures and market pressures.
Tezspire is already marketed in many countries as an add‑on therapy for severe asthma.
Want to learn even more? Click here to read the full story!